Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35583
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Opat S. | en |
dc.contributor.author | Trotman J. | en |
dc.contributor.author | Thorburn A.N. | en |
dc.contributor.author | Boulos J. | en |
dc.contributor.author | Tam C. | en |
dc.contributor.author | Cheah C.Y. | en |
dc.contributor.author | Dickinson M. | en |
dc.date.accessioned | 2021-05-14T12:01:39Z | en |
dc.date.available | 2021-05-14T12:01:39Z | en |
dc.date.copyright | 2019 | en |
dc.date.created | 20190515 | en |
dc.date.issued | 2019-05-15 | en |
dc.identifier.citation | Asia-Pacific Journal of Clinical Oncology. 15 (S3) (pp 3-11), 2019. Date of Publication: May 2019. | en |
dc.identifier.issn | 1743-7555 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/35583 | en |
dc.description.abstract | Recently, obinutuzumab was included in the Australian Pharmaceutical Benefits Scheme for use in first line, advanced or bulky stage 2, follicular lymphoma, providing more immunochemotherapy treatment options available than ever before. Rituximab with chemotherapy has been the standard of care since reimbursement in the late 1990s; however, obinutuzumab-based regimens have shown superior progression-free survival in comparison to rituximab-based options, albeit at an increased risk of grade >=3 adverse events. As median overall survival approaches 20 years or more, the long-term effects and sequencing of any strategy should be considered. Here we discuss the considerations for selection of front-line therapy, based on evidence and local Australian clinician experience, in the management of first line follicular lymphoma.Copyright © 2019 John Wiley & Sons Australia, Ltd | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Blackwell Publishing Ltd | en |
dc.relation.ispartof | Asia-Pacific Journal of Clinical Oncology | en |
dc.title | Management of patients with follicular lymphoma treated first line with obinutuzumab. | en |
dc.type | Article | en |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/ajco.13153 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 31058467 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31058467] | en |
dc.identifier.source | 627559129 | en |
dc.identifier.institution | (Opat) School of Clinical Sciences, Monash Health, Monash University, Clayton, Melbourne, VIC, Australia (Dickinson, Tam) Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia (Cheah) Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia (Tam) Department of Haematology, St Vincent's Hospital, Melbourne, VIC, Australia (Boulos, Thorburn) Roche Products Pty Ltd, Sydney, NSW, Australia (Trotman) Haematology Department, Concord Hospital, University of Sydney, Concord, NSW, Australia | en |
dc.description.address | S. Opat, School of Clinical Sciences, Monash Health, Monash University, Clayton, Melbourne, VIC, Australia. E-mail: Stephen.Opat@monashhealth.org | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2019 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | chemoimmunotherapy follicular lymphoma obinutuzumab rituximab | en |
dc.identifier.authoremail | Opat S.; Stephen.Opat@monashhealth.org | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
crisitem.author.dept | Haematology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.